Welcome to our dedicated page for Progyny news (Ticker: PGNY), a resource for investors and traders seeking the latest updates and insights on Progyny stock.
Progyny, Inc. (Nasdaq: PGNY) is a leading fertility and family building benefits company that integrates service, science, technology, and data to provide comprehensive fertility solutions for self-insured employers. The company's unique approach offers members tailored, value-based treatment plans, leveraging the latest medical advancements to improve outcomes, shorten the time to pregnancy, and reduce fertility-related costs.
Progyny's benefit plans encompass a wide range of fertility solutions, including IVF (In Vitro Fertilization), IUI (Intrauterine Insemination), embryo banking, egg freezing, adoption, and surrogacy. These plans are supported by Progyny's network of high-quality fertility specialists, known for their expertise in performing Smart Cycle treatments.
Headquartered in New York City, Progyny has established itself as a transformative leader in the fertility benefits space, partnering with employers across various industries. The company's clients benefit from a premier network of fertility and women's health specialists, advanced clinical outcomes, and reduced healthcare costs.
Progyny has been recognized for its leadership and growth, earning accolades from CNBC Disruptor 50, Modern Healthcare’s Best Places to Work in Healthcare, Forbes’ Best Employers, Financial Times, Inc. 5000, Inc. Power Partners, and Crain’s Fast 50 for NYC.
In the third quarter of 2023, Progyny reported having 392 clients, a significant increase from 282 clients in the same period in 2022. The company's financial performance includes positive Adjusted EBITDA, demonstrating robust profitability and financial health. Progyny continues to expand its services and partnerships, ensuring comprehensive support for patients and employers alike.
For more information, visit www.progyny.com. Investors can reach out to James Hart at investors@progyny.com, and media inquiries can be directed to Selena Yang at media@progyny.com.
Progyny, Inc. (Nasdaq: PGNY) reported a record revenue of $100.3 million for Q4 2020, a 54% increase from Q4 2019. For FY 2020, total revenue reached $344.9 million, up 50% year-over-year. The company also projected 2021 revenue between $520 million and $540 million, reflecting growth of 51% to 57%. Key highlights included a tripled Adjusted EBITDA and significant growth in both fertility and pharmacy benefit services. Despite challenges from the COVID-19 pandemic, Progyny's performance showcased its market resilience and expansion capabilities.
Progyny, a leader in fertility benefits management, announced its participation in the 10th Annual SVB Leerink Global Healthcare Conference on February 26, 2021, at 8:40 A.M. ET. Chief Executive Officer David Schlanger and Chief Financial Officer Mark Livingston will engage in a fireside chat at the event. Interested parties can access the live audiocast and replay via Progyny’s website. The company is recognized for redefining fertility and family building solutions, benefiting employers and patients alike.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, will release its financial results for Q4 and full year 2020 on February 24, 2021, post-market. A conference call will follow at 4:45 PM ET, offering insights into the company's performance. Participants can join via specified dial-in numbers and passcodes, with a replay available until March 3, 2021. The firm emphasizes its innovative approach to fertility solutions, aiming to benefit employers, patients, and healthcare providers. Progyny has received accolades from various organizations, highlighting its industry leadership.
Progyny, a leading fertility benefits management company, announced that CEO David Schlanger will present at the 39th Annual JP Morgan Healthcare Conference on January 12, 2021, at 3:40 P.M. Eastern Time. Following the presentation, President and COO Pete Anevski and CFO Mark Livingston will join Schlanger for a breakout session. A live audiocast and replay will be available on Progyny's website. The company is dedicated to redefining fertility benefits, providing comprehensive solutions that benefit employers, patients, and healthcare providers.
Progyny (Nasdaq: PGNY) has announced the addition of two new board members: Malissia R. Clinton and Roger Holstein, effective November 16, 2020. Clinton, with over 25 years in various industries, will serve on the Nominating and Governance Committee, while Holstein, a healthcare industry veteran, will join the Compensation Committee. Their expertise in healthcare and technology aims to provide strategic guidance as Progyny transitions to a high-growth leader in fertility benefits management. The board now consists of nine directors, enhancing the company's governance and industry insights.
Progyny, Inc. (Nasdaq: PGNY), a leader in fertility benefits management, announced that CEO David Schlanger will participate in a fireside chat at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The pre-recorded chat will be accessible from November 23 on Progyny’s website. Additionally, the company will conduct one-on-one meetings on December 1, with requests made exclusively through Piper Sandler. Progyny's innovative benefits solution aims to redefine fertility support, offering education, access to specialists, and improved clinical outcomes while reducing costs for employers.
Progyny, a leader in fertility benefits management, reported third quarter 2020 revenue of $98.9 million, up 62% from prior year. Net income hit $5.4 million, reversing an $8.2 million loss year-over-year. The company anticipates 2020 revenue guidance of $340-$345 million, targeting a growth of 48%-50%. For 2021, Progyny projects a minimum of $525 million in revenue with 180 clients covering 2.7 million lives. Adjusted EBITDA nearly doubled to $10.6 million, demonstrating strong operational leverage despite COVID-19.
Progyny, a leader in fertility benefits management, is scheduled to report its financial results for Q3 2020 on Nov. 5, 2020, after market close. A conference call will follow at 4:45 PM ET, accessible via specific dialing numbers for U.S. and international participants. An audio replay will be available until Nov. 12, 2020. Progyny is recognized for its innovative fertility solutions, enhancing access for patients while reducing healthcare costs for employers. With headquarters in New York, the company is gaining attention for its impact on fertility benefits.
Progyny (Nasdaq: PGNY) presented research at the ASRM Scientific Congress on October 17, 2020, focusing on factors influencing patient progression to infertility treatment. Analyzing 8,441 cases from 600 clinics with employer-sponsored coverage, key findings revealed that increased interactions with patient care advocates significantly boost treatment progression rates from 72% to 82%. Patients aged 35-38 were most likely to progress, while those with male infertility diagnoses showed lower progression rates. The study aims to enhance understanding of barriers patients face even when financial hurdles are addressed.
Progyny (Nasdaq: PGNY), a leader in fertility benefits management, announced the participation of its CEO, David Schlanger, in a fireside chat at the BofA Global Healthcare Conference on September 17, 2020, at 11:45 A.M. ET. This event highlights the company's commitment to redefining fertility and family-building benefits. Progyny aims to empower patients through dedicated advocacy, access to specialists, and cost reduction for employers. The event will be audiocasted live and available for replay on Progyny's website.
FAQ
What is the current stock price of Progyny (PGNY)?
What is the market cap of Progyny (PGNY)?
What services does Progyny offer?
Who are Progyny's clients?
How does Progyny's approach improve fertility outcomes?
What recognition has Progyny received?
Where is Progyny headquartered?
How many clients did Progyny have in the third quarter of 2023?
What are the financial highlights of Progyny for the third quarter of 2023?
How can investors and media contact Progyny?
What is the Smart Cycle treatment?
What makes Progyny's benefits solution unique?
